AZD0171

DRUG3 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Early-stage (II to IIIB) Non-small Cell Lung CancerLocally Advanced or Metastatic Solid TumoursNon-small Cell Lung CancerResectable

Phase 2

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Active, not recruitingNCT04999969

AstraZenecaLocally Advanced or Metastatic Solid Tumours

Start: 2021-12-10End: 2026-06-30Updated: 2026-02-03

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

RecruitingNCT05061550

AstraZenecaNon-small Cell Lung Cancer

Start: 2022-04-14End: 2030-05-28Target: 630Updated: 2026-03-11

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

RecruitingCTIS2023-508852-21-00

AstraZeneca ABEarly-stage (II to IIIB) Non-small Cell Lung Cancer, Resectable

Start: 2022-06-10Target: 493Updated: 2025-08-01

Related Papers

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

2025-05-316 citations

Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.

Journal of Clinical Oncology2025-05-28

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

Future Oncology2024-07-1830 citations

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

2023-12-1929 citations

785 mAZD0171 mediated LIF blockade in combination with chemotherapy and PD-L1 inhibition repolarizes macrophages and increases T cell infiltration via CX3CR1-CX3CL1 axis

Regular and Young Investigator Award Abstracts2023-10-311 citations

NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-0110 citations

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Cancer Immunology Immunotherapy2023-04-0589 citations

Abstract CT126: A phase 2 trial of first-line AZD0171 + durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell infiltration

Cancer Research2022-06-156 citations

Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)

Cancer Research2022-06-153 citations

Abstract 1293: AZD0171 (anti-LIF) combines productively with chemotherapy and anti-PD-L1 in mouse models of cancer

Cancer Research2022-06-152 citations